Recent research suggests that these peptides may effectively mitigate the risk of obesity and the onset of type-2 diabetes by suppressing the enzyme dipeptidyl peptidase-IV (DPP-IV), which is present in various organs, including the kidney and the gut. Here, DPP4 is linked to obesity disorder.